Guangzhou Pharmaceutical Holdings Limited manufactures pharmaceutical products. The Company produces Chinese medicines, botanical drugs, chemical raw materials, preparations, biological drugs, and other products. Guangzhou Pharmaceutical Holdings also provides business logistics distribution services.
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China,…
John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With…
A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s…
In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the…
Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one…
A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric…
One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19…
See our Cookie Privacy Policy Here
